Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2003, for Bioanalytical Systems, Inc. (BASi). The company provides laboratory services and consulting for pharmaceutical development and manufactures scientific instruments for medical research. The filing notes that the registrant is currently operating under the name Bioanalytical Systems, Inc., though the request metadata references "Inotiv, Inc." (a later name change).
Key Financial Metrics
| Metric | Q1 2004 (Ended Dec 31, 2003) | Q1 2003 (Ended Dec 31, 2002) |
|---|---|---|
| Total Revenue | $8,777,000 | $6,974,000 |
| Gross Profit | $2,635,000 | $2,685,000 |
| Operating Income (Loss) | $(84,000) | $469,000 |
| Net Income (Loss) | $(130,000) | $275,000 |
| EBITDA | $762,000 | $1,105,000 |
| Cash and Equivalents | $824,000 | $1,612,000 |
| Total Debt (Current + Long-term) | $12,578,000 | Filing does not provide clear total for prior period |
Margins: Gross margin decreased to approximately 30% (from 38.5% prior year). Operating margin turned negative at -1% (from 6.7% prior year).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 25.9% to $8.8 million, driven by two acquisitions completed in fiscal 2003 (LC Resources and PharmaKinetics) and strong product sales (Culex ABS).
- Profitability Decline: The company shifted from a net profit of $275,000 to a net loss of $130,000. This was primarily due to a 69.4% increase in General and Administrative (G&A) expenses and a significant rise in Cost of Revenue.
- Cost of Revenue: Increased to 70% of revenue (from 62% prior year) due to operating inefficiencies during acquisition integration, new staff training, and unreimbursed project overruns on one contract.
- Expense Increases: G&A expenses rose to $1.85 million due to acquisition costs, higher audit fees, and financial consulting fees following the CFO's resignation. Interest expense increased 88.2% to $207,000 due to debt incurred for acquisitions and facility expansions.
- Cash Flow: Net cash used by operating activities was $308,000, compared to $478,000 in the prior year. Cash balances decreased by $554,000 due to capital expenditures and working capital changes.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management anticipates the Baltimore facility will reach cash flow break-even in the first quarter of fiscal 2005. Expansions in Evansville and West Lafayette are complete or nearly complete.
- Liquidity Plan: The company has formulated a plan to reduce debt and improve cash flow, including selling the downtown Baltimore building, restructuring business development, and delaying capital expenditures until funded by operations.
- Covenant Compliance: The company was in violation of a financial covenant regarding interest-bearing indebtedness to EBITDA ratios for the quarter ended December 31, 2003. Banks waived compliance on January 8, 2004, and amended covenants through September 30, 2004.
- Internal Controls: A material weakness was identified in internal controls regarding the monitoring of loan covenant compliance. Management is implementing procedures to correct this.
- Unusual Items: The loss includes costs related to the resignation of the CFO and integration of new acquisitions. A specific project overrun contributed to higher service costs.
Investor Verification Checklist
- Covenant Status: Verify the current status of the amended financial covenants and the company's ability to maintain compliance through September 2004.
- Acquisition Integration: Assess whether operating inefficiencies and project overruns in the service segment are stabilizing as integration completes.
- Baltimore Facility: Monitor the progress toward the projected cash flow break-even for the Baltimore clinical research unit in Q1 fiscal 2005.
- Debt Structure: Review the terms of the construction line of credit conversion to a term note expected in April 2004 and its impact on future interest expenses.
- Internal Controls: Confirm the implementation of new procedures to monitor loan covenant compliance and prevent future material weaknesses.